HUMAN GENOME SCIENCES INC. (HGSI)

Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors 11/23/2009 07:00:01 ROCKVILLE, Md. & MONTREAL, Nov 23, 2009 (BUSINESS WIRE) -- --- Continued progress on IAP inhibitor program - Ridgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn Energy LLC, Intel Corp. and Allos Therapeutics Inc. 11/23/2009 06:39:20 LONDON, Nov 23, 2009 (MARKETWIRE via COMTEX News Network) -- Economic data fails to come to rescue for stocks as dollar plays strong on Thursday 19, 2009. Strength in the dollar kept many buyers at... Human Genome Gets FDA Response Letter for Raxibacumab Biologics License Application 11/18/2009 23:16:05 Nov 19, 2009 (Close-Up Media via COMTEX News Network) -- Human Genome Sciences, Inc. announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA)... HGSI's ABthrax Faces FDA Delay 11/18/2009 07:10:20 Nov 18, 2009 (Zacks.com via COMTEX News Network) -- Recently, Human Genome Sciences Inc. (HGSI) announced that the U.S. Food and Drug Administration (FDA) delayed the approval of ABthrax... Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application 11/16/2009 07:00:06 ROCKVILLE, Md., Nov 16, 2009 (BUSINESS WIRE) -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received a Complete Response Letter from the U.S. Food and Drug ... More News